# Ohio Launches Cannabis and Pregnancy Education Campaign > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ohio-cannabis-pregnancy-education-campaign/ > **Published:** 2026-07-23T21:29:06-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T22:02:37-04:00 > **Clinical Summary:** Ohio cannabis pregnancy campaign launches statewide. CED explains the message, evidence limits, counseling priorities, and what patients should know. --- CED Clinical Relevance #88 Fresh maternal public-health news Ohio launched the first phase of a statewide cannabis education campaign on July 23, 2026, with messaging for people who are pregnant, may become pregnant, and those who support them. The campaign creates an immediate counseling opportunity, but its commissioned survey and public messaging require careful separation from clinical outcome evidence. Clinical Insight | CED Clinic Ohio’s new campaign puts a clinically important conversation into public view: cannabis exposure in pregnancy should be discussed early, directly, and without shame. The best available human evidence is observational, not experimental, and cannot define a safe product, route, dose, or trimester. Recent systematic reviews report associations between prenatal cannabis exposure and outcomes such as preterm birth and impaired fetal growth, while also grading much of the evidence as low or very low certainty because exposure measurement, tobacco co-use, social conditions, timing, dose, and product potency are difficult to separate. Clinicians should ask what is being used, why, how often, by which route, and whether nausea, sleep, pain, anxiety, trauma, or another untreated symptom is driving use. Counseling should pair risk discussion with evidence-based alternatives and supportive follow-up, not punishment or abrupt abandonment of care. PregnancyOhioPublic Health[Cannabis Safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/)Patient Counseling Audience People who are pregnant or may become pregnant, families, obstetric clinicians, primary-care teams, and cautious readers. Primary Topic Ohio’s pregnancy-focused cannabis public education campaign and its clinical limits. Source [Read the campaign announcement](https://health.einnews.com/pr_news/928616065/oneohio-recovery-foundation-launches-pregnancy-focused-phase-of-statewide-public-education-campaign-on-cannabis-risks) Ohio has launched the first phase of a statewide cannabis education initiative focused on pregnancy and preconception. The message is clinically relevant, but readers should distinguish a public-health campaign and its commissioned survey from the lower-certainty observational evidence used to assess pregnancy outcomes. What This Study Teaches Us A public campaign can prompt earlier conversations about cannabis exposure, but a memorable message is not the same as a clinical evidence review. Good counseling connects the public warning to what is known, what remains uncertain, and the symptoms or circumstances that may be driving use. Why This Matters People may use cannabis during pregnancy for nausea, sleep, pain, anxiety, or other symptoms. A blunt warning without practical alternatives can reduce disclosure. A specific, nonjudgmental conversation gives patients and clinicians a better chance to review exposure, discuss uncertainty, and choose safer symptom-management options. Study Snapshot News Event Launch of the pregnancy-focused first phase of Ohio’s statewide cannabis education initiative Launch Date July 23, 2026 Organizations OneOhio Recovery Foundation and Ohio public-health partners Audience People who are pregnant, may become pregnant, and their support networks Campaign Basis Statewide formative research and a commissioned Ohio survey Clinical Evidence Observational studies and systematic reviews, not randomized exposure trials Key Evidence Citation Lo JO, et al. Cannabis Cannabinoid Res. 2024;9(2):470-485. doi:10.1089/can.2022.0262 Key Limit Neither campaign research nor observational outcome studies establish a safe threshold or prove causation for an individual pregnancy Clinical Bottom Line Ohio’s campaign can open a useful conversation, but pregnancy counseling should remain evidence-aware, nonjudgmental, and individualized. Opening News Brief On July 23, 2026, the OneOhio Recovery Foundation announced the first phase of Ohio’s statewide cannabis public education initiative. The initial campaign focuses on people who are pregnant, may become pregnant, and those who support them. [Campaign announcement](https://health.einnews.com/pr_news/928616065/oneohio-recovery-foundation-launches-pregnancy-focused-phase-of-statewide-public-education-campaign-on-cannabis-risks). Coverage from [Cleveland.com](https://www.cleveland.com/open/2026/07/ohio-launches-first-phase-of-marijuana-education-campaign-focused-on-pregnant-women.html), [The Toledo Blade](https://www.toledoblade.com/local/politics/2026/07/23/campaign-pregnant-ohioans-avoid-cannabis/stories/20260723081), and [The Columbus Dispatch](https://www.dispatch.com/story/news/healthcare/2026/07/23/ohio-to-combat-misinformation-on-marijuana-use-and-pregnancy/91011418007/) describes a campaign shaped by research with Ohio women and a commissioned survey about beliefs and [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) during pregnancy. For Patients and Families If cannabis is being used for nausea, pain, sleep, anxiety, trauma symptoms, or another problem, tell the prenatal care team what product is used, how often, by which route, and what symptom it is meant to address. That information helps clinicians discuss alternatives and monitor health without turning the visit into a moral judgment. Do not assume that a dispensary label, a natural origin, a medical recommendation, or a non-smoked route establishes pregnancy safety. Products vary in THC concentration, other cannabinoids, contaminants, and dose. For Clinicians Use universal, nonpunitive screening and ask about preconception use, current exposure, frequency, route, potency when known, co-use with nicotine or alcohol, and the symptom or goal behind use. When a patient wants to reduce or stop, offer a plan for the underlying symptom and arrange follow-up. Severe vomiting, dehydration, weight loss, psychiatric distress, or possible cannabis hyperemesis requires direct clinical assessment. How This Fits the Bigger Picture Ohio law directs statewide cannabis and drug-misuse education, including resources about cannabis risks during pregnancy. The new campaign is one part of that broader public-health mandate. Its practical value will depend on whether people remember the message, disclose use, receive respectful care, and gain access to effective alternatives. Awareness alone does not demonstrate improved pregnancy outcomes. What This Does Not Show The campaign launch does not establish that a particular exposure caused an outcome in any individual pregnancy. A commissioned opinion or behavior survey cannot measure fetal effects, compare products, or define a safe dose, route, frequency, or trimester. The news does not show that fear-based messaging, stigma, or punitive responses improve care. Those approaches may discourage honest disclosure. Key Clinical Caveats Randomized trials assigning cannabis exposure during pregnancy would be unethical, so the evidence base relies heavily on observational studies. Systematic reviews can adjust for some confounders, but tobacco use, social conditions, exposure timing, dose, potency, and product type remain difficult to measure. A 2024 systematic review and meta-analysis of 53 studies found associations with preterm birth, small-for-gestational-age birth, and perinatal mortality after adjustment, but rated the certainty very low to low. [Lo JO, Shaw B, Robalino S, et al. *Cannabis and Cannabinoid Research*. 2024;9(2):470-485. doi:10.1089/can.2022.0262](https://pubmed.ncbi.nlm.nih.gov/36730710/). Association does not prove that cannabis alone caused an outcome. It does support caution and an honest discussion of uncertainty. Where It Deserves Skepticism The launch announcement is a public-relations release from the organization running the campaign. Its descriptions of formative research and survey findings should not be treated as peer-reviewed clinical evidence. Campaign language may compress a complex literature into a simple warning. The clinical response should preserve the warning’s intent while acknowledging evidence limitations and avoiding unsupported precision. Policy and Public Health Angle A credible campaign should be evaluated for reach, comprehension, behavior change, disclosure, treatment access, and unintended stigma. Those outcomes matter more than impressions or advertising exposure alone. Ohio should also make clear where patients can obtain confidential prenatal care, evidence-based nausea treatment, behavioral-health support, and substance-use treatment when needed. How Strong Is This Evidence? Strong for confirming the campaign launch and its stated audience. Low to moderate for pregnancy outcome associations because the clinical literature is observational, heterogeneous, and limited by exposure measurement and residual confounding. Where This Paper Deserves Skepticism Treat the campaign’s survey as formative public-health research, not proof of clinical outcomes. Treat systematic review findings as risk signals that support caution, not as deterministic predictions for an individual pregnancy. What This Paper Does Not Show The campaign does not define a safe threshold, prove causation, compare specific products, or demonstrate that the campaign itself improves maternal or infant outcomes. How This Fits With the Broader Clinical Conversation [Cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in pregnancy may be connected to untreated nausea, pain, sleep problems, anxiety, trauma, or substance-use disorder. Effective counseling combines clear risk communication with practical alternatives, continuity of care, and freedom from shame. Dr. Caplan’s Take *The most useful part of this campaign is the invitation to have the conversation earlier. Pregnancy is not a setting for casual assurances about [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/), but it is also not a setting where shame improves medicine.* *I would ask what the patient is using, what problem it solves, and what happens when they do not use it. Then I would explain that the human evidence is observational and imperfect, yet concerning enough to favor avoidance, while helping the patient find a realistic alternative for nausea, sleep, pain, anxiety, or another symptom.* What a Careful Reader Should Take Away Take pregnancy exposure seriously, keep the evidence in proportion, and make room for honest clinical help. Evidence Interpretation Guide Table of Contents - [How to Read a Pregnancy Safety Campaign Carefully](#How_to_Read_a_Pregnancy_Safety_Campaign_Carefully)[Four questions for a careful reading](#Four_questions_for_a_careful_reading) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[Tell the Whole Story](#Tell_the_Whole_Story) - [Screen Without Punishment](#Screen_Without_Punishment) - [Support, Do Not Shame](#Support_Do_Not_Shame) - [Keep Certainty in Proportion](#Keep_Certainty_in_Proportion) - [Treat the Reason for Use](#Treat_the_Reason_for_Use) - [Routes Are Not Interchangeable](#Routes_Are_Not_Interchangeable) - [Campaign Research Is Not Clinical Proof](#Campaign_Research_Is_Not_Clinical_Proof) - [Measure More Than Reach](#Measure_More_Than_Reach) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Read a Pregnancy Safety Campaign Carefully A public-health message can be useful without being a complete evidence review. The clinical task is to connect caution with specific, supportive care. ### Four questions for a careful reading **What happened?**Ohio launched a statewide campaign phase focused on [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) during pregnancy and preconception. **What evidence supports caution?**Systematic reviews of observational studies report adverse-outcome associations, with important uncertainty and confounding. **What is still unknown?**No study defines a safe product, route, dose, frequency, or trimester, and individual causation cannot be inferred. **What should care add?**Nonjudgmental screening, symptom treatment, practical alternatives, and follow-up. The Evidence Question Can better exposure measurement clarify how timing, dose, potency, route, and co-use influence pregnancy outcomes? The Patient Question What symptom am I treating with cannabis, and what safer, evidence-based options can my care team offer? The Bottom Line A warning is most useful when it leads to a specific and supportive clinical plan. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview The campaign touches patient communication, prenatal care, symptom treatment, evidence quality, stigma, public health, product uncertainty, and policy evaluation. #### Tell the Whole Story Share product, route, frequency, and reason for use. Ask for help with the symptom cannabis is treating. Lens takeaway Disclosure should lead to support. #### Screen Without Punishment Use specific, universal questions. Pair counseling with alternatives and follow-up. Lens takeaway Trust improves clinical information. #### Support, Do Not Shame Listen before assuming why cannabis is being used. Help the patient connect with prenatal care. Lens takeaway Support keeps care accessible. #### Keep Certainty in Proportion Outcome evidence is observational. Residual confounding and exposure measurement remain important. Lens takeaway Caution does not require false certainty. #### Treat the Reason for Use Nausea, pain, sleep, and anxiety need assessment. Abrupt advice without alternatives may fail. Lens takeaway A practical plan matters. #### Routes Are Not Interchangeable Potency and dose vary across products. A non-smoked route is not established as pregnancy-safe. Lens takeaway Product details matter. #### Campaign Research Is Not Clinical Proof A commissioned survey measures beliefs or reported behavior. It does not establish pregnancy outcomes. Lens takeaway Separate messaging from evidence. #### Measure More Than Reach Track disclosure, care access, symptom treatment, and stigma. Assess whether the campaign changes health behavior. Lens takeaway Evaluation should follow the launch. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Ohio+Launches+Cannabis+and+Pregnancy+Education+Campaign&url=https%3A%2F%2Fcedclinic.com%2Fohio-cannabis-pregnancy-education-campaign%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fohio-cannabis-pregnancy-education-campaign%2F) [BlueSky](https://bsky.app/intent/compose?text=Ohio+Launches+Cannabis+and+Pregnancy+Education+Campaign%20https%3A%2F%2Fcedclinic.com%2Fohio-cannabis-pregnancy-education-campaign%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [OneOhio Recovery Foundation launches pregnancy-focused phase of statewide public education campaign on cannabis risks](https://health.einnews.com/pr_news/928616065/oneohio-recovery-foundation-launches-pregnancy-focused-phase-of-statewide-public-education-campaign-on-cannabis-risks) Related Reading at CED Clinic Continue exploring the evidence [Arkansas Pregnancy Cannabis Study Shows Persistent Medical Purchases Across Trimesters](https://cedclinic.com/arkansas-medical-cannabis-pregnancy-study/) CED coverage of a claims-based study showing continued [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) purchasing during pregnancy. [Read the Arkansas evidence review](https://cedclinic.com/arkansas-medical-cannabis-pregnancy-study/) [Prenatal Cannabis Exposure and Neurodevelopment: What the New Systematic Review Actually Shows](https://cedclinic.com/prenatal-cannabis-neurodevelopment-impact/) A careful review of neurodevelopment findings and their limits. [Review the neurodevelopment evidence](https://cedclinic.com/prenatal-cannabis-neurodevelopment-impact/) [CED Cannabis Science Digest: Pregnancy Risk Perception Signals](https://cedclinic.com/pregnancy-safety-beliefs-cannabis-risk-perception/) CED context on pregnancy safety beliefs, counseling, and evidence uncertainty. [Read the risk-perception digest](https://cedclinic.com/pregnancy-safety-beliefs-cannabis-risk-perception/) ## Frequently Asked Questions What did Ohio announce about [cannabis and pregnancy](https://cedclinic.com/cannabis-prenatal-exposure-birth-defects-colorado/)? Ohio launched the pregnancy-focused first phase of a statewide cannabis public education initiative on July 23, 2026. Who is the Ohio cannabis campaign intended to reach? It is directed toward people who are pregnant, may become pregnant, and the family members or other people who support them. Does the campaign prove cannabis causes a specific pregnancy outcome? No. A campaign and its commissioned survey do not establish clinical causation for an individual pregnancy. Is there a proven safe dose of cannabis during pregnancy? Current human evidence does not establish a safe cannabis product, dose, route, frequency, or trimester during pregnancy. What does the strongest review evidence show? Systematic reviews of observational studies report associations with several adverse [birth outcomes](https://cedclinic.com/recreational-cannabis-birth-outcomes-study-colorado/), but certainty is limited by confounding, variable exposure measurement, and study heterogeneity. Is vaping or eating cannabis safer than smoking during pregnancy? Avoiding smoke may remove combustion exposure, but no cannabis route has been established as pregnancy-safe. Why might someone use cannabis during pregnancy? Reported reasons include nausea, pain, sleep difficulty, anxiety, trauma symptoms, and established patterns of use. Each reason requires a specific clinical assessment. What should a patient tell a prenatal clinician? Share the product, route, frequency, potency when known, reason for use, co-use with nicotine or alcohol, and any difficulty reducing or stopping. What should clinicians do after a positive cannabis screen? Assess exposure and the underlying symptom, discuss evidence and uncertainty without shame, offer practical alternatives, and arrange follow-up. How should Ohio evaluate the campaign? Evaluation should include reach, understanding, disclosure, behavior change, treatment access, health outcomes, and unintended stigma. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).